Neurological Biomarkers Market is Expected to Reach $8,579.9 Million by 2025

1. Opportunity Analysis and Industry Forecast, 2016-2023 In-Depth Analysis of Neurological Biomarkers Market Global Opportunity Analysis and Industry Forecast, 2018-2025

2. Neurological Biomarkers Market Increase in demand for noninvasive neurological biomarkers is expected to supplement the market growth. Furthermore, rise in number of research activities focused towards developing efficient biomarkers that can aid in early diagnosis of Alzheimer‐™s and Parkinson‐™s diseases is expected to drive the market growth in the near future. For instance, MSDx, Inc. is developing cost-effective and reliable blood-based neurological biomarkers that can aid in detecting the onset of disease before excessive damage occurs. The company has patented the blood test and has named it as the ‐Window into The Brain. 

3. Neurological Biomarkers Market Overview Neurological Biomarkers Market for Alzheimers and Parkinsons Disease: Global Opportunity Analysis and Industry Forecast, 2017-2025, the global market was valued at $3,958.5 million in 2017, and is projected to reach $8,579.9 million by 2025, growing at a CAGR of 10.1% from 2018 to 2025. China accounted for one-ninth share of the total market of neurological biomarkers for Alzheimers in 2017. Access Full Summary : https://www.alliedmarketresearch.com/neurological-biomarkers-market The neurological biomarkers market for Alzheimers disease generated a revenue of $2,636.7 million in 2017, and is expected to reach $6,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. Conversely, neurological biomarkers market for Parkinsons disease generated a revenue of $1,321.8 million in 2017, and is expected to reach $2,457.4 million by 2025 registering a CAGR of 8.0%. 

4. Neurological Biomarkers Market The key factors that boost the growth of the neurological biomarkers market for Alzheimer’s and Parkinson’s diseases include increase in focus on developing cost-effective biomarker testing and rise in demand for noninvasive diagnostic techniques for Alzheimer’s and Parkinson’s. In addition, surge in adoption of neurological biomarkers in clinical trials supplement the market growth. However, implementation of stringent government regulations towards the approval of commercial use of biomarkers and emerging ethical issues regarding early diagnosis of Alzheimer’s and Parkinson’s diseases are expected to hamper the market growth.  Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, followed by Europe. The dominance of U.S. in the Alzheimer’s market is attributed to rise in patient population that suffers from this disease.

5. Neurological Biomarkers Market, Snapshot Neurodegenerative biomarkers for Alzheimer’s disease based on region is categorized into U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of world (ROW). U.S. was the leading market in 2017, and is expected to continue this trend throughout the forecast period. This is attributed to rise in expenditure on the management of Parkinson’s disease in the country. As of 2017, U.S. had a population of 326,506,644 individuals, and about 60,000 individuals are diagnosed with Parkinson’s diseases every year. Thus, significant prevalence of this disease among the U.S. population drives the growth of the market. However, China is projected to emerge as a lucrative market in future, due to the higher prevalence of Parkinson’s disease observed in males in 2017. The report provides a comprehensive analysis of the key players operating in the neurological biomarkers market for Alzheimer’s and Parkinson’s disease such as Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics, Immunarray Pvt. Ltd., Quanterix Corporation, Diagenic ASA, Psynova Neurotech, and Bio-Rad Laboratories. 

6. Key Findings of Neurological Biomarkers Market • Asia-Pacific is expected to register the highest growth rate from 2018 to 2025 in the neurological biomarkers market for Alzheimers. • The U.S. accounted for maximum revenue in 2017 in the market for both Alzheimers and Parkinsons, and is anticipated to maintain this trend throughout the forecast period. • EU5 region generated second highest revenue in 2017 in the market for both Alzheimers & Parkinsons, and is expected to continue this trend throughout the forecast period. • China is estimated to exhibit the highest CAGR of 10.1% from 2018 to 2025 in the neurological biomarkers market for Parkinsons disease.

7. Neurological Biomarkers Market North America Europe Asia-Pacific LAMEA

8. Neurological Biomarkers Market Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/request-sample/3555 Follow Us On